


0-10-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(1)

10/06/00

EXPRESS MAIL	MAILING LABEL NO. EL432977495US
	DATE OF DEPOSIT: OCTOBER 6, 2000
I HEREBY CERTIFY THAT THIS PAPER AND ENCLOSURES AND/OR FEE ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO: BOX PATENT APPLICATION, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231.	
EHREN RHEA (SENDER'S PRINTED NAME)	 (SIGNATURE)

Box Patent Application
 Assistant Commissioner for Patents
 Washington, DC 20231

Enclosed for filing is a patent application under 37 CFR 1.53(b) of:

Inventors: Yasmin Wadia and Scott Alan Prah
 For: BIOCOMPATIBLE ALBUMIN LAMINA AND METHOD

This application is a ☐ continuation, ☐ divisional, ☒ continuation-in-part of prior application Provisional Patent
 Serial No. 60/158,666 filed October 8, 1999.

Enclosures:

- ☒ Specification (pages 1-15); claims (pages 16-18) abstract (page 19)
- ☒ 6 sheets of informal drawings
- ☒ Declaration or Combined Declaration and Power of Attorney (unsigned)
 - ☒ Incorporation by Reference--The entire disclosure of the prior application is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
- ☒ Statement Claiming Small Entity Status (to be filed with Missing Parts)
- ☒ Non-Profit Organization (37 CFR 1.9(f) and 1.27(d))
- ☒ Return Postcard

JC542 U.S. PTO
 09/686594
 10/06/00

CLAIMS AS FILED

For	Number Filed	Number Extra	Rate	Basic Fee \$355.00
Total Claims	20-20		x \$ 9 =	
Independent Claims	3-3		x \$ 40 =	
TOTAL FILING FEE				\$355.00

Fees will be paid when Missing Parts are filed.

Customer No. 20575

Respectfully submitted,

MARGER JOHNSON & McCOLLOM, P.C.

By:

Alexander C. Johnson, Jr.
 Reg. No. 29,396

Marger Johnson & McCollom, PC
 1030 SW Morrison, Portland, OR 97205
 (503) 222-3613

5 BIOCOMPATIBLE DENATURED ALBUMIN LAMINA AND METHOD

 This application claims priority from U.S. Serial No. 60/158,666, filed
October 8, 1999, and incorporated by reference.

10

 BACKGROUND OF THE INVENTION

 The invention relates generally to biological tissue welding, and more
specifically to repairing a lesion to a solid visceral organ. The invention also relates
15 to manufacturing biocompatible albumin lamina suitable for use as a scaffold or
patch in the repair of tissue of a solid visceral organ.

 Solid visceral organs such as the liver, spleen and kidney have a soft
parenchyma richly interspersed with vasculature and thinly protected by a delicate
fibrous capsule with limited internal fibrous support. This structure makes such
20 organs prone to fracture and laceration with blunt abdominal trauma. Such organs
are also frequently injured following abdominal trauma. For example, the liver is
the most commonly injured organ following abdominal trauma. It is the second
most commonly injured following blunt injuries and the third most commonly
injured in penetrating injuries.

25 Surgery of solid visceral organs like liver, spleen and kidney have always
proved to be challenging, as these organs bleed profusely if traumatized and hold
sutures rather poorly. Exsanguinating hemorrhage remains a significant cause of
immediate mortality. A 3cm parenchymal depth laceration has a 19% mortality and
a parenchymal disruption involving 25–50% of a hepatic lobe has 28% mortality.

30 Few intra-abdominal injuries are as technically demanding as a major liver
laceration. Such wounds require erudite judgment and innovative surgical
techniques to prevent intraoperative exsanguination accelerated in some cases by
hemodilution and coagulopathy. Conventional suture repair of major hepatic trauma
additionally has a delayed morbidity and mortality from septicemia, peritonitis,

biliary fistulae, and delayed intra-abdominal hemorrhage.

The current surgical armamentarium for liver lacerations is limited to mass ligation of the lacerated liver with absorbable sutures, omental wrapping, packing with re-exploration, mesh hepatorrhaphy, fibrin sealant and ultrasonic aspiration with argon beam coagulation. Suture repair of the liver frequently increases parenchymal damage and ischemic tissue loss. Packing can be complicated by persistent hemorrhage and/or abdominal compartment syndrome and requires re-exploration to remove the packing. Biliary fistula and abscess formation can also complicate this technique. These difficulties also arise in repairing lesions in the kidney and spleen. They also present an obstacle to surgical treatment of solid visceral organs, for example, excision of tumors.

The use of lasers alone to control hemorrhage in the liver has had limited success in the past. Tissue coagulation is the method of heating to denaturation the constituents of the tissue itself. Attempts at hemostasis using the CO₂ laser have failed to show significant benefit when compared to the diathermy. Other work showed that the CO₂ laser is ineffective at sealing vessels larger than 1mm and that argon and Nd:YAG lasers are ineffective at stopping flow in vessels larger than 4.5mm. These lasers achieve hemostasis by extensive (5–10mm depth) thermal coagulation of proteins, causing major collateral tissue damage.

The use of laser energy to join tissue by heating a protein solder, typically albumin, is referred to as tissue welding. Laser soldering has been employed as an alternative to suture repair of injured tissues. Laser soldering was first utilized to anastomose rat ureters. Incorporating albumin solder into laser repairs was found to aid in controlling hemorrhage.

Solders are generally viscous liquids of biocompatible compositions. A representative composition is that of U.S. Pat. No. 5,292,362 (to Bass et al.), which discloses a liquid solder of collagen or albumin. Liquidity permits the solder to be easily applied and formed to the lesion, while its concentration serves to retain the solder at the applied site until irradiated. The highest viscosity of albumin readily producible corresponds to a 55-57% aqueous solution, enabling higher tensile strength weld joints. However, this albumin solder solution has the approximate

consistency of honey. Higher concentrations of albumin, i.e., above 58%, dehydrate rapidly and cannot be freely handled in air.

It was recognized that adding a light-absorbing chromophore to the solder would increase and localize the absorption of energy to the solder level, thereby
5 reducing both the amount of laser light required and collateral tissue damage. A chromophore is utilized to increase and localize the absorption of energy. The selection of chromophore also drives the choice of laser energy to be applied. For example, by using indocyanine green (ICG) as the exogenous chromophore, a diode laser could be operated at 800nm. These lasers have the advantage of being
10 relatively inexpensive. Further, their near-infrared light is poorly absorbed by solid visceral organ tissue, substantially mitigating thermal damage during a laser repair. Lastly, the specific absorption of energy by the chromophore pinpoints the heat generation locus to the solder layer. Reducing the amount of laser light required for solder activation permits lower laser energy settings. More efficient energy
15 absorption also allows the use of pulsed lasers, further reducing collateral thermal damage during laser repairs.

Tissue welding using only an ICG-augmented albumin solder confers no advantage in some scenarios. Soldering can be employed to achieve hemostasis of severed liver venous sinusoids of larger diameters (i.e., 5mm and above). However,
20 the weld joints produced are brittle and of relatively low tensile strength. Previous repairs focus on nerve, ureter and vesicular and usually further include stay sutures. Solid visceral organs require a support contribution from the repair material. Solders exhibit low tensile strength and are not well-suited to provide this support. To date, laser soldering applications have not shown a clear benefit over
25 conventional suture repair, and have not gained clinical acceptance

Mechanical considerations also militate against effecting lesion repair with irradiated liquid solder. Welding liver requires the application of an ICG-doped albumin solution to the weld area. As the ICG absorbs the laser light energy, the amount of ICG present (e.g., the thickness of the applied solution) is a significant
30 factor in weld success and duplication. The non-uniformity in the albumin layer thickness during tissue repair is currently the greatest source of variability in laser

repair using albumin solder.

Blood, bile and other fluids routinely exude from lesions. During laser solder repair, this seepage displaces the liquid solder from the surface of the damaged organ. Because of its viscosity, liquid solders cannot easily be manipulated to regain contact with the lesion site, instead necessitating deposit of further solder material and/or exposure of the lesion to additional energy. Alternatively, the fluids are irradiated and/or trapped beneath the welded solder material. Such entrapped weld joint contaminants adversely affect joint quality, strength and durability.

Laser soldering alone is also suboptimal for the repair of resecting injuries to solid visceral organs. Satisfactory repair of raw surface lesions is typically obtained with folding of the tissue or the application of some sort of a supportive film, described below. In addition to its bond strength, laying down and irradiating an uneven solder cover is likely to produce thinner, weaker points in the tissue weld. The longevity of repairs of raw surface traumas using only liquid solder is therefore suspect.

Efforts have also been made to repair damage to nerves and small vessels using solid welding patches, such as small pieces of dried albumin (1x3x0.5mm strips). Further, such strips possess a low tensile strength, making them unsuitable for gross repairs such as resection or blunt trauma injuries. Lastly, these materials have been employed to repair nerves, ureters and other vessels. A need exists to direct the method of tissue welding to tissues possessing soft parenchyma, such as the liver, kidney and other solid visceral organs.

Solid biocompatible materials have been employed to repair injuries to tissues needing greater structural support than is offered by solder alone. Compositions include gelatin (U.S. Pat. No. 5,931,165 to Reich et al.); elastin (U.S. Pat. No. 6,110,212 to Gregory, et al.); and collagen (U.S. Pat. No. 5,749,895 to Sawyer et al.). Sawyer et al. teach making and using a sheet preferably made of collagen. The reference also mentions albumin as one of a number of alternative candidate materials. However, Sawyer et al. provide no description of the manufacture, method of use or physical characteristics of an albumin film. Further,

none of the prior art references describe using an albumin film in the repair of injuries to solid visceral organs, such as liver, kidney and spleen.

Different methods have been attempted by Applicant to produce useful thin films of albumin. Prior efforts to extrude 55–57% albumin failed, as the solution would re-congeal upon exiting the extrusion orifice. Consequently, a need exists for a stable, pliable albumin lamina.

Applicant has experimented with welding liver lesions in liver by the application of ICG-doped liquid albumin solder to the weld area. As it is the ICG that absorbs the laser light energy, the thickness of the applied solution is a critical factor in weld success and repeatability. To date, this variable has not been controllable and the need for accurate and uniform albumin application persists. The albumin lamina of the present invention addresses this need by focusing on the preparation of thin albumin films, providing for the application of albumin of uniform and consistent thickness to a weld site.

Applications of energy to living tissue have the additional drawback of thermal damage to the lesion site under repair. The degree of damage varies according to the energy type and the amount applied, but can in some cases be substantial. In tissue coagulation, for example, the tissue is literally melted and then fused. An argon ion beam coagulator, used in this procedure, produces damage penetrating 3–4 mm into the tissue. While this repair technique seals the surface over an incision, superficial injury is sustained by the organ parenchyma well beyond the precise area of the incisive trauma. Such thermal damage also increases the risk of improper healing, spawning fistulae and other unwanted post-procedural complications. While thermal damage is more limited in soldering, a need exists to further minimize and control damage to healthy tissue surrounding or adjacent to a lesion in a locus of repair.

The present invention relates to the use of laser welding techniques on liver, kidney and spleen – solid tissues that are notoriously difficult to repair with sutures. Applicant's experimental efforts achieved rapid hemostasis of *in vivo* liver lacerations (10 cm long and 1 cm deep) and lobar resections (5 by 2 cm) in swine. However, an integral part of the success of the swine experiments was the use of the

changes its state from a viscous liquid to a flexible solid.

Another aspect of the present invention is a method for using the albumin lamina according to the present invention to repair a lesion on a solid visceral organ. The method comprises welding the albumin lamina over a lesion on a solid visceral organ. A laser solder is deployed beneath the lamina to weld it to the organ surface. In alternative embodiments, the albumin lamina is produced with additives in the form of bio-active agents.

Further details and advantages of the present invention will be apparent from the following detailed description, in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a physical representation of an albumin lamina according to the present invention.

FIG. 2 is a scatter-plot of ultimate strength data for one embodiment of the lamina of **FIG. 1**.

FIG. 3 is a scatter-plot of elasticity data for one embodiment of the lamina of **FIG. 1**.

FIG. 4 is a scatter-plot of ultimate strength data as a function of curing temperature, curing time and curing method in the manufacture of lamina according to one aspect of the present invention.

FIG. 5 shows a method of making a denatured albumin lamina according to one embodiment of the invention.

FIG. 6 shows a method of repairing a lesion to a solid visceral organ surface using a denatured albumin lamina according to one embodiment of the invention.

DETAILED DESCRIPTION

As used hereinafter, the terms "percent" and "%" refer to weight per volume (gm/100dl) unless otherwise noted.

The albumin lamina of the present invention is made from FDA-approved human serum albumin. It is therefore completely biocompatible and biodegradable.

Typically, other biomaterials (gelatin, collagen or elastin) are culled from animal sources. These materials engender attendant concerns about antigenicity, immune rejection and foreign body reactions. Furthermore, transmission of animal viruses and diseases is a concern. Use of human serum albumin substantially mitigates these concerns, as the protein sequence and structure vary little between individuals. As well, human serum albumin is amenable to sterilization and obviates the risk of animal diseases crossing species barriers into humans.

A typical lamina 10, shown in FIG. 1, is a film having a predetermined thickness. The preferable thickness is 200 μ m, although the lamina can be manufactured to greater or lesser thicknesses in a range of 75 μ m to greater than 300 μ m. A denatured albumin lamina is clear, thin, flexible and preferably of uniform thickness. It can be manipulated by hand easily and without special care, due to its sufficiently high tensile strength and pliability. Although possessive of slight tackiness, it does not bond or stick to itself.

The denaturation leaves the lamina stable in a variety of environments. The denatured albumin lamina will not solubilize in water or saline solution or after contact with tissue. The denatured albumin lamina of the present invention is also stable in air. The denatured lamina requires vacuum storage but maintains its pliancy for as long as approximately 15 minutes on the benchtop.

Several advantages are provided by the denatured albumin lamina patch in tissue welding over the prior art. First, its relative insolubility enables the user to reposition the lamina after placement on a lesion site. In contrast to prior welding patch materials, the denatured albumin lamina can be glided over the organ surface. Furthermore, the denatured lamina can be picked up for removal or repositioning.

Second, the lamina results in a welded albumin layer of uniform thickness because of its consistent dimensions. This uniformity eliminates weak spots in the tissue weld, caused by thin areas in the soldering or welding materials.

Third, the lamina can be impregnated with one or more bioactive agents, comprising pharmaceuticals, hormones, hemostatic agents, or other therapeutic agents. Spot-welding the lamina to the lesion site avoids irradiation of the entirety of the lamina, preserving such compounds during the welding process. Compounds

can be selected which are not damaged by the particular energy type used in the welding method.

Fourth, the denatured albumin lamina can be sterilized by autoclaving or gamma irradiation. Because denaturation is desired, autoclaving can accomplish both the sterilization and denaturation steps in the manufacture of the lamina.

A study was done of albumin lamina cured at 100°C for 30, 60, 120, 200, 300, and 600 seconds in which a dog bone die was used to cut the albumin strips so that the failure point was consistently in the middle of the sample, rather than at the clamps. Strips of approximately 2x1cm were pulled in a Chatillon Materials Tester. Ultimate strength was calculated by dividing the cross-sectional area of the test strip into the force required to break the test strip.

Ultimate strength results are shown in **FIG. 2**. The ultimate strengths were recorded along with the exact width and thickness of each sample. The ultimate strength was calculated by dividing the force required to break the sample by the cross-sectional area (width x thickness).

Ultimate strength is seen in **FIG. 2** to increase almost linearly up until 200 seconds, after which strengths vary only trivially. The data indicate that there may be a strength increase in the sheet, if it is cured at temperatures exceeding 95°C.

FIG. 3 shows the elasticity of albumin strips denatured at 100°C. Young's modulus of elasticity was calculated for each sample by a linear fit of stress/strain data for strains ranging from 0 to 0.1. For denatured albumin strips cured at 100°C, the stiffness (Young's modulus) increases with increasing curing time, with the most increase occurring in the first 200 seconds.

FIG. 4 shows the ultimate strengths in kilopascals for albumin strips denatured by heat bath immersion at 85°C, 90°C and 95°C. As well, the effects were assessed of heating by autoclaving at 110°C, with and without a brief (15–30 second) heat bath immersion prior to autoclaving.

There is an increase in strength in the 600 second data over the shorter cure times. However, there is no significant change in strength between 15 second and 60 second curing times. Moreover, there is no significant difference in strength between the three different temperatures tested.

Elasticity was also influenced by boiling time. Boiling for periods beyond 200 seconds had only a minor impact on lamina elasticity.

Overall, temperatures of at least 90°C are needed to achieve strips with an acceptable ultimate strength. Only a marginal increase in both ultimate strength and elasticity was imparted by boiling in excess of 200 seconds.

The denatured albumin lamina of the present invention has varied applications. It can be employed as a substrate for temporary external integument replacement in burn treatment or other areas of extensive tissue loss. In this use, the capacity of the lamina to be impregnated with antibiotics or other bioagents is particularly beneficial. Alternatively, the lamina may be manufactured with substantial structure in all three dimensions. A lamina so cast is useful as a scaffolding, for example, in the tissue-engineering of organs.

To make denatured albumin lamina according to the present invention, a liquid albumin solution of approximately 53% to 57% is utilized. In a preferred embodiment, the albumin solution is concentrated to 53–55%.

FIG. 5 shows a method of making denatured albumin lamina. In a first step **500**, the concentrated albumin **52** is placed between two nonporous sheets **51**, e.g., the main panels of a Kapak bag plastic. Typically, approximately 1cc of albumin solution is placed between the edges of the two aligned plastic sheets. These sheets are then placed in another Kapak bag **55** (not shown in steps **510** and **520** for clarity) and the entire unit rolled **510** through a rolling mill **53**, forward and backward, to spread the albumin evenly **520** and to a uniform thickness **52**. The roller **54** height can be calibrated using known thickness of materials placed between the rollers. After rolling, the outer bag is evacuated **530**, i.e., with a vacuum pump/trap **56**, and the open edge heat-sealed (not shown).

At this point, the entire package is placed **540** in a hot water bath **57** of controlled temperature to denature the albumin. During the heating step, the albumin protein is denatured. It is believed that the molecules interact and form a polymer upon cooling..

Alternatively, sheets are cured at 90°C for 15 seconds and then autoclaved at 110°C for 10 minutes. In yet another embodiment, albumin lamina is denatured by

autoclaving only.

The factors most greatly impacting the properties of the resultant denatured albumin lamina are serum albumin solution concentration (50–57%), curing temperature (86–120°C), curing time (15 seconds to 10 minutes) and curing pressure (1–3 atm).

The denatured albumin lamina are typically double-packaged and stored to prevent dehydration and maintain pliancy. While so stored, the lamina can be gamma-irradiated (25–35 Gy) to sterilize the biomaterial and container.

A method of using the denatured albumin lamina of the present invention in the repair of lesions on solid visceral organs is herein disclosed. Efficacy has been assessed directly in benchtop experiments.

As illustrated in **FIG. 6**, a lesion **60** on a solid visceral organ can be repaired using the denatured albumin lamina of the present invention. The repair begins with the application to the lesion site of a quantity of an energy-absorbing material **62**.

One such material is liquid albumin solution (solder) doped with a chromophore. In a preferred embodiment, solder of 53% to 55% albumin is used, further containing ICG at a concentration of approximately 0.1 mg/ml.

The lesion site is then irradiated **620** with energy **64** from an energy source **66**. Because the solder is energy-absorbing, it denatures. Surface tissue in contact with the solder also heats and denatures. With sufficient energy irradiation, fusion of sinusoids results in substantial hemostasis at the lesion site. In *in vivo* applications, this step serves to achieve substantial hemostasis at the lesion site. While hemostasis is not necessary for the subsequent laminar welding with high strength, hemostasis is a desired consequence of the lesion repair. Blood loss is thereby further minimized and the lesion more efficaciously treated.

A denatured albumin lamina **68** according to the present invention is then placed **630** over the welded energy-absorbing material **62** on the lesion site **60**. Alternatively, the lamina is first trimmed to roughly conform to the particular dimensions of the lesion.

The lesion site is then again irradiated **640** with energy **64** from an energy source **66**. The lamina, being transparent to the laser light at the chosen wavelength,

absorbs little light energy and hence heats minimally as compared to the solder. The energy-absorbing material beneath the lamina absorbs energy and heats, conducting heat to the lamina. With sufficient energy irradiation, the albumin solder and the denatured albumin lamina are denatured at the protein level. It is believed that the albumin molecules intertwine with one another and with tissue. Upon cooling, the lesion site is weld-sealed, wherein the denatured albumin lamina and the lesion site are welded together.

In the benchtop experiments, lacerating lesions were made to the surface of a porcine liver. Reinforcement by an albumin lamina gives hepatic lesion repairs a measured continuity and prevents accidental de-lamination of the soldered albumin from the liver. The albumin lamina also increases the welded surface area, holding the lacerated edges together much like an integumentary bandage across cut skin edges.

In a preferred embodiment, the lesion site is irradiated **620** with energy **64** after the deposition **610** of solder **62** and before the placement thereon **630** of the denatured albumin lamina **68**.

In liver surgery, rapid hemostasis in presence of coagulation failure may be necessary. Hepatic lesion repair, performed according to a less preferred embodiment of the current method, achieved complete hemostasis at a rate of about 9.4 sec/cm². This modality effectively seals the liver surface and joins lacerations with minimal thermal injury. Further, the present method works independently of the patient's coagulation status.

FEATURES AND BENEFITS

The successful treatment of lesions using denatured albumin lamina and a laser offers a new modality of treatment of lesions in the liver and other solid visceral organs of humans. Conventional suture repair of the liver is strongly influenced by the skill of the surgeon. In contrast, the low pressure portal vein and hepatic vein make the liver suitable for tissue welding. It is relatively simple to repair an injured liver effectively using the present invention, primarily because of the visual change in the albumin solder as it is irradiated. This allows one to

recognize when a sufficient number of laser pulses have been delivered.

One drawback to tissue welding is that a dry operating field is needed, necessitating Pringle's maneuver perform the procedure. Therefore, for grade IV and V liver trauma repair, total hepatic isolation may be required. The ten minutes
5 required to complete a laser repair of the liver is well within ischemic time tolerated by the liver. The time required for tissue welding is comparable to suture repair. This time can be shortened by using larger laser spot sizes with correspondingly higher laser pulse energies. Another advantage of laser soldering is that the 800nm laser energy is selectively absorbed by ICG dye; accidental misdirection of the laser
10 beam at the energy levels used had no effect on the surrounding viscera. More rapid repairs may be dictated by those patients presenting with other critical injuries; i.e., extensive trauma or injuries to numerous body sites.

A benefit of the present invention is its mitigation of collateral damage inflicted upon the tissue during repair. The damage sustained by the liver in the
15 above examples was significantly less for tissue weld repairs (typically 0.5–1.0mm) than the 1cm ischemic region seen in the conventional suture repair. During tissue welding, thermal damage is confined primarily to the albumin on the surface, with some heating of the surface of the liver caused by heat conduction. This depth of damage is about an order of magnitude smaller than that of other techniques that rely
20 on thermal coagulation of parenchyma to achieve hemostasis (e.g., electrocoagulation, argon ion beam coagulation, and focused ultrasound). Even suture repair is accompanied by a significant layer of ischemic parenchyma that may eventually become necrotic with attendant complications.

The denatured albumin lamina are stable and retain their transparent quality
25 even when heated to the high temperatures of 80°C to 120°C that are required for laser welding. The lamina needs to be energy-transparent at these temperatures so that the laser light reaches the albumin-ICG solder interface unrestricted. Collagen and other protein scaffold materials denature at 60°C. They also cloud over and restrict laser light penetration. Small intestinal submucosa, peritoneum and
30 pericardium – all transparent collagen biomaterials – curl, shrink and coagulate when used in tissue welding.

09686594-100600
Tissue welding can reduce the morbidity and mortality associated with bleeding, biliary leakage, and sepsis following liver surgery. The direct resection of invading tumors, primary hepatomas or other neoplasms buried deep within the parenchyma is therefore feasible. This resection is possible because the remaining
5 raw organ surfaces could be welded with the albumin patch according to the present invention. Further, major hepatic resection for trauma or malignancy need no longer be done along anatomical planes. Patch welding enables resection of damaged or diseased liver along non-anatomical planes, thereby simplifying surgery and preserving hepatic parenchyma. Finally, patch welding can be translated without
10 undue experimentation to the repair of other solid visceral organs such as the spleen and kidney.

Because it does not use endogenous coagulation pathways for hemostasis, the method of organ repair according to the present invention holds promise for repair of solid visceral organ trauma even in the presence of coagulation failure or
15 heparin. Experimental animals were given a single dose of heparin to imitate the coagulopathy that is usually seen in liver trauma.

Tissue welding is safe, quick and reliable in the presence of heparin. Repairs of porcine liver injuries using a method according to the present invention were straight-forward and resulted in small volumes of parenchymal damage. This
20 technique can potentially reduce the morbidity and mortality associated with liver trauma and injury.

The lesion repair method of the present invention can be performed in conventional open surgical procedures, i.e. where access to internal body tissues and/or organs is achieved through a relatively large percutaneous surgical incision
25 permitting laminar placement and exposure of the tissue/lamina to energy. The albumin lamina of the present invention can thus be introduced by the surgeon while directly viewing the target region and manipulating the lamina through the incision. Alternatively, the method of the present invention for welding tissue can be performed via less invasive surgical events, e.g., by laparoscopy, thoracoscopy,
30 arthroscopy, or the like. Such procedures typically rely on creating small percutaneous penetrations and accessing the target region through cannulas placed

within such penetrations. The target region is viewed through an associated viewing scope. In both open surgical procedures and less invasive procedures, the lamina will typically be trimmed to desired dimensions and configuration prior to placement on the tissue.

5 A person skilled in the art will be able to practice the present invention in view of the present description, where numerous details have been set forth in order to provide a more thorough understanding of the invention. In other instances, well-known features have not been described in detail in order not to obscure unnecessarily the invention.

10 Having described and illustrated the principles of the invention in a preferred embodiment thereof, it should be apparent that the invention can be modified in arrangement and detail without departing from such principles. All modifications and variations are claimed which come within the spirit and scope of the following claims.

CLAIMS

What is claimed is:

1. A biocompatible lamina **10**, comprising denatured serum albumin in a solid state having sufficient water content to be pliable, formed into a film having a thickness **12** in a range of 75µm to 300 µm.

2. The biocompatible lamina of claim 1, wherein the serum albumin has a concentration of 50% to 57% w/v.

2a. The biocompatible lamina of claim 1, wherein the lamina has a thickness **12** of about 250 µm.

3. The biocompatible lamina of claim 1, having a tensile strength of at least about 625 kPa.

4. The biocompatible lamina of claim 1, having an elasticity of about 1700 kPa to 4000 kPa.

5. The biocompatible lamina of claim 1, further comprising a chromophore.

6. The biocompatible lamina of claim 1, further comprising at least one biologically active agent.

7. A method of manufacturing a denatured albumin lamina **10**, comprising:

providing two nonporous sheets **54** arranged in substantially parallel apposition so as to define a space **60** of substantially uniform thickness between the nonporous sheets;

flowably interleaving a serum albumin solution **52** in the space between the nonporous sheets;

enclosing the interleaved serum albumin solution and nonporous sheets in a container 61;

evacuating the container; and

heating the container sufficiently to convert the serum albumin solution
5 between the nonporous sheets into a solid albumin film.

8. The method of claim 7, wherein the nonporous sheets are apposed a spacing of not less than about 75 μ m.

10 9. The method of claim 7, wherein the serum albumin solution has a concentration of about 50% to 58%.

10. The method of claim 7, wherein the serum albumin solution further includes a chromophore.

15 11. The method of claim 7, wherein the serum albumin solution further includes at least one biologically active agent.

12. The method of claim 7, wherein heating the container involves
20 exposing the container to a temperature greater than about 86° C.

13. The method of claim 7, wherein the container is heated for at least about one minute.

25 14. A method of repairing a lesion on a solid visceral organ, comprising:
applying an energy-absorbing material to a lesion site on the solid visceral organ lesion;

irradiating the proteinaceous fluid with energy sufficient to fuse the energy-absorbing material at least partially to the surface at the lesion site;

30 applying a biocompatible denatured albumin lamina onto the energy-absorbing material on the lesion site; and

irradiating the biocompatible albumin lamina and the proteinaceous fluid with energy sufficient to fuse the biocompatible albumin lamina to the surface at the lesion site.

5 15. The method of claim 14, wherein the layer is irradiated sufficiently to achieve substantial hemostasis at the lesion site.

16. The method of claim 14, wherein the biocompatible albumin lamina has an albumin concentration of about 50% to 58%.

10 17. The method of claim 14, further comprising the step of clamping off blood supply to the lesion site of the solid visceral organ.

18. The method of claim 14, wherein the energy-absorbing material is a
15 fluid and is applied to a thickness of 100–1000 μm .

18a. The method of claim 18, wherein the wherein the energy-absorbing material is a fluid and is applied to a thickness of 100–250 μm .

20 19. The method of claim 14, wherein the energy-absorbing material comprises a chromophore and the energy is light energy of a wavelength absorbed by the chromophore to fuse the biocompatible albumin lamina to the lesion site.

25 20. The method of claim 19, wherein the biocompatible albumin lamina is translucent to light energy.

BIOCOMPATIBLE DENATURED ALBUMIN LAMINA AND METHOD

ABSTRACT OF THE INVENTION

5

The present invention provides a denatured albumin lamina, useful for repairing lesions on solid visceral organs. The lamina comprises human serum albumin, formed into a thin, pliant sheet and denatured. The denatured lamina can be sterilized and stored until used. As well, it can be impregnated with a variety of
10 bioagents.

In another aspect of the present invention, a method is provided for manufacturing the denatured albumin lamina. The method comprises placing a quantity of 50% to 60% (preferably 53%–55%) albumin solution between two nonporous sheets, then spreading the albumin solution between the sheets to a
15 selected and substantially uniform thickness, e.g., 200 μm . The albumin solution sandwich thus formed is placed into a container, which is then evacuated. The sandwich is heated (cured), by autoclaving or immersion in a water bath of at least 86°C (preferably 90°C for five minutes). Denaturation of the entrapped albumin solution changes its state from a viscous liquid to a flexible solid with tensile
20 strength and pliability. Ultimate strength of the flexible solid lamina is directly related to starting albumin solution concentration, curing temperature and curing time.

Another aspect of the present invention is a method comprising welding the albumin lamina to a lesion site on a solid visceral organ. A laser solder can be
25 deployed beneath the lamina to aid in welding it to the organ surface using laser light energy.

00900T" 46598960




FIG 1

01




FIGURE 2









FIGURE 3

Cook Time (s)	Cooked and Autoclaved (kPa)	Autoclaved (kPa)	90°C (kPa)	85°C (kPa)
15	460	460	460	460
30	440	440	440	440
60	440	440	440	440
120	440	440	440	440
250	440	440	440	440
500	1120	920	750	650

FIGURE 4

0958594-100600



540

Fig. 5

0050074598960 09636594-100500







FIG. 6

COMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
BIOCOMPATIBLE ALBUMIN LAMINA AND METHOD, the specification of which:

- ☒ is attached hereto.
☐ was filed on _____ as Application No. _____
☐ and was amended on _____ (if applicable)
☐ with amendments through _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Sec. 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Sec. 119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Claiming Priority?	
			<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, Sec. 119(e) of any United States provisional application listed below:

<u>Provisional Application No.</u>	<u>Filing Date</u>
<u>60/158,666</u>	<u>October 8, 1999</u>

I hereby claim the benefit under Title 35, United States Code, Sec. 120 or §365(c) of any PCT international application designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the

prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Sec. 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Sec. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application No.) (Filing Date) (Status) (patented, pending, abandoned)

I hereby appoint the following attorneys to prosecute the application, to file a corresponding international application, to prosecute and transact all business in the Patent and Trademark Office connected therewith:

Customer No. 20575

<u>Attorney Name</u>	<u>Registration No.</u>
Jerome S. Marger	26,480
Alexander C. Johnson, Jr.	29,396
Alan T. McCollom	28,881
James G. Stewart	32,496
Glenn C. Brown	34,555
Stephen S. Ford	35,139
Julie L. Reed	35,349
Gregory T. Kavounas	37,862
Scott A. Schaffer	38,610
Joseph S. Makuch	39,286
James E. Harris	40,013
Graciela G. Cowger	42,444
Ariel Rogson	43,054
Craig R. Rogers	43,888

Direct all telephone calls to Alexander C. Johnson, Jr. at (503) 222-3613 and send all correspondence to:

Alexander C. Johnson, Jr.
MARGER JOHNSON & McCOLLOM, P.C.
1030 S.W. Morrison Street
Portland, Oregon 97205

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of co-inventor: Yasmin Wadia

Inventor's signature: _____

(Date)

Residence: Beaverton, Oregon

Citizenship: Indian

Post Office address: 380 N.W. Island Circle, Apartment B-4
Beaverton, Oregon 97006

Full name of co-inventor: Scott Alan Prah

Inventor's signature: _____

(Date)

Residence: Portland, Oregon

Citizenship: United States

Post Office address: 4014 N.E. Knott
Portland, Oregon 97212